Table 2.
The performance characteristics of spectrometric methods reported in the literature for rifamycins determination.
| Analyte | Method | Wavelength (nm) | LR (µg/mL) |
LOD (µg/mL) | Sample | Ref. |
|---|---|---|---|---|---|---|
| RIF | direct water |
474 | 0.82–65.38 | - | Pharmaceuticals; urine, plasma | [138] |
| RIF | HCl H3PO4 |
263 259 |
1.50–30.00 | 0.19 0.14 |
Pharmaceuticals; urine | [141] |
| RIF | PBS pH 7.00 | 470 | 8.00–128.00 | 0.16 | - | [142] |
| RIF | direct ethyl acetate |
334 | 2.50–35.00 | 0.83 | Combined dosage forms | [136] |
| RIF ISN |
AA water |
337 263 |
5.00–35.00 5.00–25.00 |
1.65 0.59 |
Combined dosage forms | [125] |
| RIF ISN RIF ISN |
AA methanol 1D methanol |
338 263 263 290 |
5.00–50.00 | 3.50 2.60 2.30 1.30 |
Combined dosage forms | [126] |
| RIF PYR |
1D methanol |
365 247 |
4.00–12.00 | 0.87 0.82 |
- | [127] |
| RIF Piperine |
Q-AR methanol |
387 337 |
5.00–40.00 2.00–20.00 |
1.51 0.28 |
Combined dosage forms | [128] |
| RIF CC-I |
Q-AR methanol:water |
370 239 |
2.00–20.00 1.00–24.00 |
0.043 0.014 |
In-house combined formulation | [129] |
| RIF PYR ISN RIF PYR ISN RIF PYR ISN |
DRSZ DDRD HDDR |
358 252 294 350 259 293 292 324 & 345 279 & 286 |
5.00–30.00 5.00–30.00 5.00–30.00 2.00–30.00 2.00–30.00 |
2.14 1.39 1.76 1.76 1.62 1.8 0.64 0.43 1.61 |
Pharmaceuticals; urine | [130] |
| RIF | Chloranilic acid | 510 | 7.90–39.10 | - | Pharmaceuticals | [143] |
| RIF | DDQ TCNQ TCNQ p-chloranil Fe (III) |
584 680 761 560 540 |
5.00–140.00 5.00–120.00 2.00–45.00 15.00–200.00 10.00–240.00 |
2.59 2.09 0.90 3.95 2.30 |
Pharmaceuticals | [139] |
| RIF | FCR Indirect/Fe(III) + K3[Fe(CN)6] |
760 750 |
1.00–35.00 2.50–50.00 |
0.32 0.32 |
Pharmaceuticals; urine | [140] |
| RIF | Indirect/NBS + KI | 572 | 0.50–15.50 | - | Pharmaceuticals; urine; plasma | [138] |
| RIF ISN |
Cu(II) + neocuproine/ PLS regression |
8.00–57.00 5.50–7.00 |
0.06 0.04 |
Combined dosage forms; urine | [132] |